Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
Francis J. Giles(Northwestern University), Elihu H. Estey(University of Washington), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Alexandria T. Phan(Methodist Hospital), Steve Kornblau(The University of Texas MD Anderson Cancer Center), Cynthia L. David(The University of Texas MD Anderson Cancer Center), Dawn Colburn(The University of Texas MD Anderson Cancer Center), Asif Rashid(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(Washington University in St. Louis), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Tracey A. Waddelow(The University of Texas MD Anderson Cancer Center)
Cited by 280
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k